Methylprednisolone for the treatment of acute spinal cord injury: Counterpoint

Neurosurgery

Volumn 61, Issue , 2007, Pages 36-42

  Fehlings, Michael G ^a,b,c   Wilson, Jefferson R ^a   Cho, Newton ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MINOCYCLINE; NALOXONE; NIMODIPINE; PLACEBO; RILUZOLE; STEROID; TIRILAZAD; NEUROPROTECTIVE AGENT;

CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL RESEARCH; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; INJURY SEVERITY; INTENSIVE CARE UNIT; META ANALYSIS; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINAL CORD DECOMPRESSION; SPINAL CORD INJURY; SPINE SURGERY; STEROID THERAPY; SYSTEMATIC REVIEW; WOUND INFECTION; DRUG USE; EVALUATION STUDY; EVIDENCE BASED PRACTICE; FOLLOW UP; MEDICAL EXAMINATION; SYSTEMATIC REVIEW (TOPIC); CLINICAL TRIAL (TOPIC); SPINAL CORD INJURIES;

CLINICAL TRIALS AS TOPIC; HUMANS; METHYLPREDNISOLONE; NEUROPROTECTIVE AGENTS; SPINAL CORD INJURIES;

EID: 84922357567     PISSN: 0148396X     EISSN: 15244040     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000412     Document Type: Conference Paper

References (32)

1. O'Connor P. Survival after spinal cord injury in Australia. Arch Phys Med Rehabil. 2005;86(1):37-47.
2. Martins F, Freitas F, Martins L, Dartigues J, Barat M. Spinal cord injuries epidemiology in Portugal's central region. Spinal Cord. 1998;36(8):574-578.
3. Ackery A, Tator C, Krassioukov A. A global perspective on spinal cord injury epidemiology. J Neurotrauma. 2004;21(10):1355-1370.
4. Rick-Hansen-Institute. High Cost of Healthcare. Vancouver: 2012. Available at: http://www.rickhanseninstitute.org/en/information-about-sci/high-cost-of-healthcare. Accessed December 12, 2012.
5. Wilson JR, Forgione N, Fehlings MG. Emerging therapies for acute traumatic spinal cord injury. CMAJ. 2013;185(6):485-492.
6. Lammertse D, Dungan D, Dreisbach J, et al. Neuroimaging in traumatic spinal cord injury: an evidence-based review for clinical practice and research. J Spinal Cord Med. 2007;30(3):205-214.
7. Cadotte DW, Wilson JR, Mikulis D, Stroman PW, Brady S, Fehlings MG. Conventional MRI as a diagnostic and prognostic tool in spinal cord injury: a systemic review of its application to date and an overview on emerging MRI methods. Expert Opin Med Diagn. 2011;5(2):121-133.
8. Kirshblum SC, Burns SP, Biering-Sorensen F, et al. International standards for neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med. 2011;34(6):535-546.
9. Hadley M, Walters B, Grabb P, et al. Blood pressure management after acute spinal cord injury. Neurosurgery. 2002;50(3 suppl):S58-S62.
10. Hadley M, Walters B, Grabb P, et al. Management of acute spinal cord injuries in an intestive care unit or other monitored setting. Neurosurgery. 2002;50(3 suppl):S51-S57.
11. Wilson J, Fehlings M. Emerging approaches to the surgical management of acute traumatic spinal cord injury. Neurotherapeutics. 2011;8(2):197-204.
12. Fehlings MG, Rabin D, Sears W, Cadotte DW, Aarabi B. Current practice in the timing of surgical intervention in spinal cord injury. Spine (Phila Pa 1976). 2010; 35(21 suppl):S166-S173.
13. Hawryluk GW, Rowland J, Kwon BK, Fehlings MG. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus. 2008;25(5):E14.
14. Rowland J, Hawryluk G, Kwon B, Fehlings M. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008;25(5):E2.
15. Hall ED, Braughler JM. Effects of intravenous methylprednisolone on spinal cord lipid peroxidation and Na++K+)-ATPase activity. Dose-response analysis during 1st hour after contusion injury in the cat. J Neurosurg. 1982;57(2):247-253.
16. Hurlbert RJ, Hadley MN, Walters BC, et al. Pharmacological therapy for acute spinal cord injury. Neurosurgery. 2013;72(suppl 2):93-105.
17. Hadley M, Walters B, Grabb P, et al. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery. 2002;50(3 suppl):563-572.
18. Fehlings MG, Vaccaro A, Wilson JR, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PLoS One. 2012;7(2):e32037.
19. Bracken MB, Collins WF, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA. 1984;251(1):45-52.
20. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322(20):1405-1411.
21. Otani K, Abe H, Kadoya S. Beneficial effects of prednisolone sodium succinate in the treatment of acute spinal cord injury. Sekitsy Sekizui. 1994;7:633-647.
22. Petijean ME, Pointillart V, Dixmerias F, et al. Traitment medicamenteux de la lesion medullaire traumatique au stade aigu. Ann fracaises d'anesthesie de reanimation. 1998;17(2):115-122.
23. Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M, Yamada H. Early complications of high-dosemethylprednisolone sodium succinate treatment in the followup of acute cervical spinal cord injury. Spine (Phila Pa 1976). 2001;26(4):426-430.
24. Hugenholtz H. Methylprednisolone for acute spinal cord injury: not a standard of care. CMAJ. 2003;168(9):1145-1146.
25. Hugenholtz H, Cass DE, Dvorak MF. High dose methylprednisilone for acute closed spinal cord injury-only a treatment option. Can J Neurol Sci. 2002;29(3):227-235.
26. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;17(20):1405-1411.
27. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev. 2012;1:CD001046.
28. Wilson JR, Cadotte DW, Fehlings MG. Clinical predictors of neurological outcome, functional status, and survival after traumatic spinal cord injury: a systematic review. J Neurosurg Spine. 2012;17(1 suppl):11-26.
29. Burns AS, Ditunno JF. Establishing prognosis, and maximizing functional outcomes after spinal cord injury: a review of current and future directions in rehabilitation management. Spine (Phila Pa 1976). 2001;26(24 suppl):S137-S45.
30. Fehlings MG. Clinical Trials.gov: riluzole in spinal cord injury study (RISCIS). 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01597518? term=riluzole1AND1spinal1cord1injury&rank=1. Accessed 2012.
31. Casha S. Minocycline in acute spinal cord injury (MASC). NCT01828203. ClinicalTrials.gov. 2013. Available at: ClinicalTrials.gov.
32. Wilson JR, Arnold PM, Singh A, Kalsi-Ryan S, Fehlings MG. Clinical prediction model for acute inpatient complications after traumatic cervical spinal cord injury: a subanalysis from the Surgical Timing in Acute Spinal Cord Injury Study. J Neurosurg Spine. 2012;17(1 suppl):46-51.